Remix Therapeutics
Healthcare & Life Sci
Company overview
Remix Therapeutics develops small molecule therapeutics that modulate RNA processing. Its REMaster Platform is a proprietary drug discovery platform for designing small molecules that control RNA processing. REM-422, its lead program, is an investigational first-in-class small molecule mRNA degrader that targets the pre-mRNA of MYB. The company is headquartered in Watertown, Massachusetts.
Remix Therapeutics is private. In June 2026 it announced a merger with Passage Bio, alongside a $100 million private placement.
- Industry
- Healthcare & Life Sci
- Headquarters
- United States